Drug
ADG116
ADG116 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
NCT04501276
completedphase_1
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05277402
terminatedphase_1
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
NCT04111445
Clinical Trials (3)
Showing 3 of 3 trials
NCT04501276Phase 1
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
NCT05277402Phase 1
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT04111445Phase 1
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3